Edwards Lifesciences (NYSE:EW) Price Target Cut to $75.00 by Analysts at Truist Financial

Edwards Lifesciences (NYSE:EW - Free Report) had its target price decreased by Truist Financial from $78.00 to $75.00 in a report released on Friday morning,Benzinga reports. Truist Financial currently has a hold rating on the medical research company's stock.

A number of other research analysts also recently commented on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Finally, Evercore ISI dropped their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus target price of $78.55.

Edwards Lifesciences Trading Up 0.6 %

NYSE EW traded up $0.40 on Friday, reaching $71.16. The company had a trading volume of 1,716,754 shares, compared to its average volume of 4,899,717. The stock has a market cap of $41.83 billion, a price-to-earnings ratio of 10.21, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $95.25. The stock's 50 day moving average is $71.27 and its 200-day moving average is $70.76. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,353 shares of company stock valued at $5,197,442 over the last ninety days. 1.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently made changes to their positions in the stock. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $30,000. Finally, Park Square Financial Group LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $44,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.